Drug

Pharmacologic Class

Indication

More Information
Dermatological Disorders
Olumiant (baricitinib) Janus kinase inhibitor Treatment of adults with severe alopecia areata. Olumiant Drug Monograph
Gastrohepatic Disorders
Skyrizi (risankizumab-rzaa) Interleukin-23 antagonist Treatment of moderately to severely active Crohn disease in adults. Skyrizi Approved for Moderately to Severely Active Crohn Disease
Immunization
Priorix (measles, mumps rubella vaccine, live) Measles, Mumps Rubella Vaccine, Live For active immunization for the prevention of measles, mumps and rubella in individuals 12 months of age and older. FDA Approves Additional Option for Measles, Mumps and Rubella Vaccination
Oncology
Breyanzi (lisocabtagene maraleucel)  
CD19-directed genetically modified autologous T cell immunotherapy.
Treatment of adult patients with large B-cell lymphoma, including diffuse large B-cell lymphoma not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have:refractory disease to first-line chemoimmunotherapy or relapse within 12 months of first-line chemoimmunotherapy; or refractory disease to first-line chemoimmunotherapy or relapse after first-line chemoimmunotherapy and are not eligible for hematopoietic stem cell transplantation due to comorbidities or age. Breyanzi Drug Monograph
Tafinlar + Mekinist (dabrafenib + trametinib) Kinase inhibitor Treatment of individuals 6 years of age and older with unresectable or metastatic solid tumors with BRAF V600E mutation, who have progressed following prior treatment and have no satisfactory alternative treatment options. Tafinlar-Mekinist Combo Wins Tumor-Agnostic Indication for BRAF V600E Solid Tumors
Rare Diseases
Amvuttra (vutrisiran)
Chemically modified double-stranded small interfering ribonucleic acid that targets mutant and wild-type transthyretin messenger RNA
 Treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. Amvuttra Approved for Polyneuropathy of Hereditary Transthyretin-Mediated Amyloidosis
Imcivree (setmelanotide) Melanocortin receptor agonist Treatment of chronic weight management in patients 6 years of age and older with monogenic or syndromic obesity due to Bardet-Biedl syndrome. Imcivree Drug Monograph

Topics:

Alopecia Cardiovascular Disease Crohn Disease Dermatological Disorders Gastrohepatic Disorders Hematologic Disorders Immunization Inborn Errors Of Metabolism Leukemias/lymphomas/ And Other Hematologic Cancers Measles Metabolic Disorders Oncology Rare Diseases Vaccines